First Human Challenge Testing of a Pneumococcal Vaccine - Double Blind Randomised Controlled Trial.
CONCLUSIONS: PCV reduced pneumococcal colonisation rate, density and duration in healthy adults. The experimental human pneumococcal colonisation model is a safe, cost-effective and efficient method to determine the protective efficacy of new vaccines on pneumococcal colonisation; PCV provides a 'gold standard' against which to test these novel vaccines. Clinical trial registration available at www.isrctn.com, ID 45340436.
PMID: 26114410 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, Wang D, Morton B, Ferreira DM, Gordon SB Tags: Am J Respir Crit Care Med Source Type: research
More News: Bacterial Pneumonia | Clinical Trials | Hepatitis | Hepatitis A | Hepatitis Vaccine | Meningitis Vaccine | Pneomococcal Vaccine | Pneumonia | Respiratory Medicine | Study | Vaccines